Compare WEA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEA | ANIX |
|---|---|---|
| Founded | 2002 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.4M | 103.9M |
| IPO Year | N/A | 2013 |
| Metric | WEA | ANIX |
|---|---|---|
| Price | $9.66 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 65.9K | ★ 179.3K |
| Earning Date | 01-01-0001 | 09-09-2026 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.52 | $2.32 |
| 52 Week High | $11.42 | $5.46 |
| Indicator | WEA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 39.52 |
| Support Level | $9.55 | $2.51 |
| Resistance Level | $10.46 | $3.09 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 21.05 | 5.75 |
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.